NEW YORK (GenomeWeb News) – Millipore will be the worldwide distributor of the ACTCellerate human progenitor cell lines under a co-marketing agreement signed with BioTime subsidiary Embryome Sciences, BioTime said yesterday.
The ACTCellerate line is derived from human embryonic stem cells but not fully differentiated into specific cell types and are used in drug discovery, research, and development. BioTime said that the cell lines are generated using a two-step multiplex process that rapidly isolates and purifies progenitor cells from different lineages.
Millipore will initially offer six novel progenitor cell lines and optimized ESpan growth media for in vitro propagation of each cell line. The firms expect to jointly launch 35 cell lines and associated growth media over the next 12 months.
"We believe that Embryome Sciences' novel, highly-purified, and scalable progenitor lines have potential to be a significant breakthrough for the industry," Donald O'Neil, director of marketing for stem cells and cell biology at Millipore, said in a statement.
Financial and other terms of the alliance were not disclosed.